Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : TAK save search
Takeda to Present Data at 65th American Society of Hematology (ASH) Annual Meeting, Demonstrating Continued Commitment to Patients with Hematologic Diseases
Published: 2023-11-27 (Crawled : 14:00) - biospace.com/
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: 0.0%
H: 0.42%
C: 0.21%
FRUZAQLA™ (fruquintinib) Now Available from Onco360 for the Treatment of Adult Patients with Metastatic Colorectal Cancer (mCRC)
Published: 2023-11-21 (Crawled : 18:00) - biospace.com/
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: 0.07%
H: 0.57%
C: 0.0%
cancer treatment
The European Commission Approves Label Update for TAKHZYRO® (lanadelumab), Expanding Its Use to a Broader Group of Paediatric Patients with Recurrent Attacks of Hereditary Angioedema (HAE)
Published: 2023-11-17 (Crawled : 15:30) - prnewswire.com
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: 1.75%
H: 0.32%
C: -0.07%
takhzyro label update group
COVID-19 Challenges Drive the Need for Resilient Supply Chains and Digital Healthcare in the Anti-Epileptic Drugs Market, Shaping the Post-Pandemic Landscape
Published: 2023-11-06 (Crawled : 19:00) - prnewswire.com
GLAXF | News | $19.54 -14.18% 2.6K
|
Health Technology
|
| O: 0.41%
H: 0.0%
C: 0.0%
VTRS | News A | $11.55 1.67% 1.65% 7.2M
|
Health Technology
|
| O: 0.11%
H: 0.33%
C: -0.98%
TEVA | $13.01 -0.68% 7.5M
|
Health Technology
|
| O: 0.22%
H: 1.49%
C: -0.33%
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: 0.44%
H: 0.22%
C: 0.07%
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: 0.24%
H: 0.18%
C: 0.16%
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: 0.18%
H: 0.0%
C: 0.0%
GSK | News | $40.86 -0.92% -0.15% 1.7M
|
Health Technology
|
| O: 0.55%
H: 0.3%
C: 0.0%
ABT | News | $106.89 -0.65% -0.22% 5.1M
|
Health Technology
|
| O: -0.42%
H: 0.0%
C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -1.32%
H: 0.0%
C: 0.0%
covid-19
Incyte to Spotlight More Than 40 Hematology and Oncology Abstracts Including a Plenary Presentation at the ASH Annual Meeting
Published: 2023-11-02 (Crawled : 18:00) - biospace.com/
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: 1.03%
H: 0.73%
C: 0.58%
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: -1.09%
H: 1.03%
C: 0.91%
XNCR | $19.05 3.7% 3.57% 760K
|
Health Technology
|
| O: 1.32%
H: 0.45%
C: -1.19%
MOR | News | $18.07 0.17% 0.17% 130K
|
Health Technology
|
| O: 2.22%
H: 0.6%
C: -9.4%
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: -0.28%
H: 1.0%
C: -0.46%
presentation meeting
ImmunoGen Reports Recent Progress and Third Quarter 2023 Financial Results
Published: 2023-11-02 (Crawled : 13:00) - biospace.com/
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: 1.03%
H: 0.73%
C: 0.58%
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 4.42%
H: 0.0%
C: 0.0%
IMGN | News | $31.23 0.03% 49M
|
Health Technology
|
| O: 5.09%
H: 5.48%
C: -1.27%
financial results
Kadcyla Leads the Global Antibody Drug Conjugates Market with Extensive Use in Breast Cancer Treatment
Published: 2023-11-01 (Crawled : 18:00) - prnewswire.com
ALPMY | News | $9.49 -1.11% 480K
|
Manufacturing
|
| O: -1.46%
H: 3.67%
C: 3.26%
ZYME | $8.555 -0.06% -0.06% 590K
|
Health Technology
|
| O: 1.14%
H: 0.42%
C: -0.7%
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: 1.03%
H: 0.73%
C: 0.58%
ADCT | $4.78 -3.82% 0.0% 280K
|
Health Technology
|
| O: -0.16%
H: 6.42%
C: 4.49%
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
|
| O: -0.86%
H: 0.0%
C: 0.0%
STRO | $3.47 -6.72% -7.2% 540K
|
Health Technology
|
| O: 0.39%
H: 3.86%
C: 3.86%
IMGN | News | $31.23 0.03% 49M
|
Health Technology
|
| O: 5.09%
H: 5.48%
C: -1.27%
GILD | $67.07 0.06% 0.06% 8.3M
|
Health Technology
|
| O: -0.47%
H: 1.88%
C: 1.78%
EXEL | $23.7 1.76% 1.73% 1.5M
|
Health Technology
|
| O: -2.62%
H: 1.17%
C: -1.66%
drug antibody breast cancer treatment global market
Incyte Reports 2023 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
Published: 2023-10-31 (Crawled : 00:00) - biospace.com/
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: 1.05%
H: 0.74%
C: 0.74%
XNCR | $19.05 3.7% 3.57% 760K
|
Health Technology
|
| O: -0.41%
H: 2.1%
C: 1.11%
MOR | News | $18.07 0.17% 0.17% 130K
|
Health Technology
|
| O: 4.23%
H: 0.12%
C: -1.97%
MGNX | $15.7 -3.27% -3.38% 520K
|
Health Technology
|
| O: 0.0%
H: 2.13%
C: 1.16%
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: -0.39%
H: 4.09%
C: 3.8%
financial results
Global Gastroparesis Treatment Market is Expected to Grow Revenue up to USD 11.09 Billion By 2030 with a Growing CAGR of 3.3% | Infinium Global Research
Published: 2023-10-27 (Crawled : 10:00) - prnewswire.com
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: 0.6%
H: 0.74%
C: 0.07%
PCSA | $1.67 4.38% 4.19% 40K
|
Producer Manufacturing
|
| O: -1.15%
H: 5.05%
C: 2.7%
expected treatment research global growing market
Takeda Announces FY2023 H1 Results; Updates Full-Year Forecasts While Remaining on Track Towards Management Guidance
Published: 2023-10-26 (Crawled : 08:00) - biospace.com/
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: -4.69%
H: 0.69%
C: -3.18%
fy2023 management
Global Bleeding Disorders Treatment Market Surpasses $14 Billion in 2022, Expected to Reach $20.3 Billion by 2028
Published: 2023-10-25 (Crawled : 22:00) - prnewswire.com
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: -4.69%
H: 0.69%
C: -3.18%
NVO | News | $126.16 -1.93% -0.23% 3.1M
|
Health Technology
|
| O: -1.47%
H: 0.22%
C: -0.83%
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: 0.1%
H: 0.0%
C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.09%
H: 0.0%
C: 0.0%
bleeding expected reach disorders treatment global market
European Commission Approves ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage III Hodgkin Lymphoma in Combination with AVD
Published: 2023-10-18 (Crawled : 22:00) - biospace.com/
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: -1.61%
H: 0.14%
C: -0.27%
cd30 adcetris treatment
Takeda Settles Tax Dispute with Irish Revenue over Break Fee Received by Shire
Published: 2023-10-18 (Crawled : 11:00) - biospace.com/
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: -1.61%
H: 0.14%
C: -0.27%
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
|
| O: 1.24%
H: 0.23%
C: 0.01%
Larimar Therapeutics Appoints Dr. Jeffery W. Sherman to its Board of Directors
Published: 2023-10-03 (Crawled : 20:00) - globenewswire.com
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: -2.07%
H: 0.19%
C: -0.07%
LRMR | $6.46 0.0% 220K
|
Health Technology
|
| O: -1.27%
H: 0.0%
C: -2.42%
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: -0.0%
H: 0.03%
C: 0.02%
therapeutics
Takeda Launches New App to Help Healthcare Professionals Keep Pace with Important Clinical Trial Data
Published: 2023-10-03 (Crawled : 12:30) - biospace.com/
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: -2.55%
H: 1.07%
C: 0.4%
trial
HUTCHMED Announces Submission of New Drug Application for Fruquintinib for Previously Treated Metastatic Colorectal Cancer in Japan
Published: 2023-09-29 (Crawled : 09:00) - globenewswire.com
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: -0.51%
H: 0.42%
C: -0.26%
HCM | $18.405 0.85% 0.84% 58K
|
Health Technology
|
| O: 0.59%
H: 0.82%
C: -0.65%
drug japan application submission
Global Bleeding Disorders Market Set to Surge, Expected to Reach $25.97 Billion by 2032 with a 6.6% CAGR
Published: 2023-09-27 (Crawled : 02:00) - prnewswire.com
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: -0.69%
H: 0.0%
C: 0.0%
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: 0.56%
H: 0.06%
C: -0.62%
NVO | News | $126.16 -1.93% -0.23% 3.1M
|
Health Technology
|
| O: -0.51%
H: 0.62%
C: 0.42%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.5%
H: 0.0%
C: 0.0%
GRFS | $6.4 -1.23% -1.25% 960K
|
Health Technology
|
| O: -0.22%
H: 1.09%
C: -0.55%
bleeding expected reach disorders global set market
Takeda Announces Approval of CUVITRU™ Subcutaneous Immunoglobulin in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia
Published: 2023-09-25 (Crawled : 15:00) - biospace.com/
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: 0.57%
H: 0.38%
C: 0.25%
japan approval
Global Antifibrinolytic Drugs Market Soars to $16.2 Billion in 2022, Driven by Rising Trauma Cases and Surgical Applications
Published: 2023-09-20 (Crawled : 00:00) - prnewswire.com
VTRS | News A | $11.55 1.67% 1.65% 7.2M
|
Health Technology
|
| O: -0.4%
H: 0.2%
C: -1.52%
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: -1.66%
H: 0.0%
C: -0.56%
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: -0.7%
H: 0.06%
C: -0.75%
global market
Takeda Announces FDA Acceptance of NDA Resubmission of TAK-721 (budesonide oral suspension) for the Short-Term Treatment of Eosinophilic Esophagitis (EoE)
Published: 2023-09-20 (Crawled : 14:00) - biospace.com/
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: 0.12%
H: 0.43%
C: -0.18%
tak-721 fda resubmission treatment
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.